# WAKIX Net Revenue Hits Record $261M in Q2 2026, Company Reaffirms $1B+ Annual Guidance

> news · REPORTED · 2026-07-21

Harmony Biosciences pre-announced that WAKIX net revenue grew 30% year-over-year to a record approximately $261 million in Q2 2026 and reaffirmed full-year 2026 net revenue guidance of $1.0 to $1.04 billion, with full financial results reported on August 4, 2026.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases, with its lead product WAKIX (pitolisant) approved for narcolepsy.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: biotech
- Primary source: https://ir.harmonybiosciences.com/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.